Czechia – Antithrombotic agents – Antitrombotika X. - Eliquis
Opportunity Score
Confidence: 40%
Complexity: low
11 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation
AI Analysis Summary
Open tender for the supply of the antithrombotic medicinal product Eliquis (apixaban) to the Institute for Clinical and Experimental Medicine (IKEM) in Prague, Czech Republic. The contract is for 48 months with an estimated value of 15,334,000 CZK. Award is based solely on price. Only Czech language submissions are accepted.
Strengths
Documents available
Open procedure
Low complexity
Risks
Submission deadline in 11 days
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
- Bids must be submitted electronically via the NEN profile.
- Submission language must be Czech (CES).
- Variants are not allowed.
Award Criteria
nabídková cena
celková nabídková cena
| Criterion | Type |
|---|---|
nabídková cena celková nabídková cena | Price |
Buyer
Name
Institut klinické a experimentální medicíny
Location
Praha, CZE
Website
Buyer profile
Identifier
00023001
Lots (1)
Supply of oral medicinal products containing the active substance apixaban (ATC group B01AF02 - HVLP Eliquis) for patients in approved indications according to the SPC valid at the date of bid submission. Duration 48 months.
Procurement Details
Publication
27 May 2026
Deadline
26 Jun 2026, 11:00
Procedure
open
Contract
supplies
Duration
48 MONTH
Language
CES
Publication #
365156-2026
Classification
Performance: Czech Republic
Documents (2)
Opportunity Score
Confidence: 40%
Complexity: low
11 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation